Blueprint Medicines Corporation

Good morning, my name is Charlie and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Bluepoint Medicine second quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, please press star followed by two. Please plan to limit yourself to one question. Thank you. Jenna Cohen, you may begin your conference.

Thank you, Charlie. Good morning, everyone, and welcome to Blueprint Medicine's second quarter 2022 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at www.blueprintmedicines.com. Joining me on today's call are Kate Haviland, our Chief Executive Officer, who will discuss our successes in the second quarter and a look ahead to the second half of the year. Felina Lee, our Chief Commercial Officer, who will provide a commercial update. Becker Hughes, Chief Medical Officer, who will provide a clinical update. Christy Rossi, Chief Operating Officer, who will review our 2022 milestone progress and upcoming catalyst. and Mike Lansdell, our Chief Financial Officer, who will review our second quarter 2022 financial results. Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factor section of SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements. I'll now turn the call over to Kate. Kate?

Thanks, Jenna, and good morning, everyone. Thank you for joining the call today. At Blueprint, we continue to build one of the world's leading precision therapy companies, with a diversity of growth drivers across all stages of our business, including two globally commercialized revenue-generating medicines, multiple important clinical development programs across a range of prevalent and hard-to-treat cancers, a prolific early discovery engine, and a strong cash position. Blueprint had a strong quarter with $36.5 million in total revenues, including $28.5 million in Avakit net product revenues. The 20% Avakit quarter-over-quarter revenue growth underscores the strength of our ongoing commercial launch as we continue to solidify Avakit as the standard of care for the treatment of advanced systemic mesocytosis. Our launch in Advanced SM has demonstrated broad prescriber receptivity to Avakit's clinical profile, strong launch execution that has facilitated access and limited payer hurdles, and an elevated patient awareness leading to increased diagnosis and treatment rates. it has also continued to improve our understanding of the non-advanced SM market, and the significant opportunity Avakit has to meet the medical needs of these patients as we look to our registration-enabling Pioneer Part 2 top-line data readout later this month. We ended the quarter with the announcement of a transformative $1.25 billion non-dilutive financing that ensures we have the resources and operational flexibility to drive Blueprint's long-term growth, while maintaining our path to financial independence. This financing enables acceleration of our broad pipeline and an ability to continue to explore opportunities for synergistic and strategic business development. Business development has played a key role in Blueprint's value creation and long-term portfolio growth, and has allowed us to fully realize the value of our prolific discovery platform. Today, we are happy to announce that we have outlicensed our internally discovered KIT Exon 13 inhibitor to IDRX, a newly launched clinical stage company. Christy will provide an overview of the transaction later during the call. And finally, we plan to provide additional insights into our breadth of growth drivers at our Investor Day, which will take place on November 1st of this year in New York City. We look forward to sharing our strategic vision for Blueprint with our near-term focus on the important growth opportunity in SM, as well as outlining how we are driving mid-term value through our EGFR mutant and CDK2 vulnerable cancer development programs, and how we're creating long-term value through our research innovation and vision. The depth and breadth of what we will cover at the Investor Day demonstrates our unique company profile and the strong position we have to continue to deliver significant value to patients and all of our other stakeholders. With that, let me turn the call over to Felina to discuss our commercial updates. Felina?